- Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
- Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
- Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
- Teva to Present at the 2024 Bank of America Healthcare Conference
- Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
- U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
- Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
- Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
- Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
More ▼
Key statistics
On Thursday, Teva- Pharmaceutical Industries Ltd. (TEVA:TLV) closed at 6,129.00, -2.67% below its 52-week high of 6,297.00, set on May 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6,180.00 |
---|---|
High | 6,227.00 |
Low | 6,103.00 |
Bid | 6,126.00 |
Offer | 6,129.00 |
Previous close | 6,244.00 |
Average volume | 2.66m |
---|---|
Shares outstanding | 1.13bn |
Free float | 1.13bn |
P/E (TTM) | -- |
Market cap | 68.30bn ILS |
EPS (TTM) | -1.64 ILS |
Data delayed at least 20 minutes, as of May 16 2024 15:24 BST.
More ▼